Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 Year follow-up naturalistic study

Actas Espanolas de Psiquiatria

Volumn 34, Issue 1, 2006, Pages 7-15

  Mayoral, F ^a   Montejo, A L ^b   Bousono M ^c   Gonzalez Torres M A ^d   Olivares, J M ^e   Ros, S ^f   Sanjuan J ^g   Escobar, Rodrigo ^h,j   Lara, N ⁱ  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

^e HOSPITAL XERAL CÍES   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g UNIVERSITY OF VALENCIA   (Spain)

^h DCRandT   (Spain)

ⁱ Health Outcomes Research Europe   (Spain)

^j ELI LILLY AND COMPANY   (Spain)

more..

Author keywords

Olanzapine; Quality of life; Schizophrenia; Social functioning

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN RELATION; MALE; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL BEHAVIOR; STATISTICS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERPERSONAL RELATIONS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR;

EID: 33645026406     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Johannessen JO. Review: lifetime prevalence of schizophrenia and related disorders is about 5.5 per 1,000, but there is significant variation between regions. Can J Psychiatry 2002;47:833-43.
2. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Evid Based Ment Health 2003;6:74.
3. Carpenter WT, Buchanan RW. Medical progress: schizophrenia. N Engl J Med 1994;330:681-90.
4. Chan S, Yu lu W. Quality of life of clients with schizophrenia. J Adv Nurs 2004;45:72-83.
5. Awad AG, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997;11:32-47.
6. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomised clinical trial. Qual Life Res 1999;8:417-26.
7. Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomised double-blind trial in Australia and New Zealand. Schizophr Res 2003;61:303-14.
8. Dennis A. Revicki, Laura A. Genduso, Susan H. Hamilton, Dara Ganoczy, Charles M. Beasley Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999;8:417-426.
9. Rothwell PM. Can overall results of clinical trials be applied to all patients. Lancet 1995;345:1616-9.
10. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olazanpine trial. Neuropsychopharmacology 1996;14:111-23.
11. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:470-18.
12. Badia X, del Llano J. Health outcomes research. Med Clin (Barc) 2000;114(Suppl. 3):1-7.
13. Gómez JC, Sacristán JA, Hernández J, Breier A, Ruiz Carrasco P, Antón Saiz C, et al, for the EFESO Study Group. The safety of olanzapine compared with other antypsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO study). J Clin Psychiatry 2000;61:335-343.
14. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002;1;57:201-8.
15. Cuesta JM, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001;48:17-28.
16. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, et al, on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcome (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-32.
17. Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB, SOHO Study Group. The European Schizophrenia Outpatiens Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand Suppl 2003;416:7-15.
18. The EuroQoL Group. EuroQoL a new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
19. Prieto L, Sacristán JA, Ormaechea JA, Gómez JC. Euroqol 5D (a generic health-related quality of life measure): psychometric validation in a sample of schizophrenic patients. Eur Neuropsychopharmacol 2002;12:300.
20. Badia X, Roset M, Montserrat S, Herdman M, Segura A. La versión española del EuroQoL: descripcion y aplicaciones. Med Clin 1999;112(Suppl. 1):79-85.
21. Torres A, Olivares JM. Validacion en castellano de la Social Functioning Scale (escala de Funcionamiento Social). Actas Esp Psiquiatr 2005;33:216-20.
22. Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry 1998;59(Suppl. 12).
23. Lee S, Lee MT, Chiu MY, Kleinman A. Experience of social stigma by people with schizophrenia in Hong Kong. Br J Psychiatry 2005;186:153-7.
24. Angermeyer MC, Beck M, Dietrich S, Holzinger A. The stigma of mental illness: patients' anticipations and experiences. Int J Soc Psychiatry 2004;50:153-62.
25. Ristner M, Farkas H, Gibel A. Satisfaction with quality of life varies with temperament type patients with schizophrenia. J Nerv Ment Dis 2003;191:668-74.
26. Bechdolf A, Klosterkotter J, Hambrecht M, Knost B, Kuntermann C, Schiller S, Pukrop R. Determinants of subjective quality of life in post acute patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2003;253:228-35.
27. Reine G, Lanchón C, Di Tucci S, Sapin C, Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scan 2003;108:297-303.
28. Jarema M, Konieczynska Z, Murawiec S, Szafranski T, Szaniawska A. The change of quality of life and clinical picture in schizophrenia. Psychiatr Pol 2002;36:393-402.
29. Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J Clin Psychiatry 1999;60(Suppl. 5):23-30.
30. Ritchie CW, Chiu E, Harrigan S, May K, Hassett A, Macfarlane S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003;18:432-40.
31. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000;15:245-55.
32. Hamilton SH, Revicki DA, Genduso LA, Besley CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998;18:41-9.
33. José Manuel Montes, Antonio Ciudad, Josep Gascón, Juan Carlos Gómez, EFESO Study Group. Safety, effectiveness and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:667-74.
34. Franz M, Lis S, Plüddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997;170:422-5.
35. Villares C, Sartorius N. Challenging the stigma of schizophrenia. Rev Bras Psiquiatr. 2003;25:1-2.
36. Heinrichs DW, Hanlon Te, Carpenter Wt Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.